{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-030631","form_type":"8-K","ticker":"ICCC","cik":"0000811641","company_name":"IMMUCELL CORP /DE/","filed_at":"2025-10-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:42.237868+00:00","generated_at":"2026-05-17T04:31:36.049108+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"ImmuCell Q3 sales fall 8% to $5.5M; 9-month sales up 7% to $20M","bullets":["Preliminary Q3 2025 product sales $5.5M vs $6.0M in Q3 2024, an 8% decrease.","Nine-month 2025 sales $20.0M, up 7% from $18.7M; trailing twelve-month sales $27.8M, up 16%.","Drop attributed to end of distributor restocking that boosted H1 2025; guidance warned of H2 softening.","Re-Tain Investigational Product use started in controlled study with Michigan State; no revenue expected.","Non-Administrative NADA for Re-Tain submitted Jan. 2025; clearance of contract manufacturer inspection remaining hurdle."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-030631","json":"https://secwatch.observer/filing/0001437749-25-030631.json","markdown":"https://secwatch.observer/filing/0001437749-25-030631.md","text":"https://secwatch.observer/filing/0001437749-25-030631.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/811641/000143774925030631/0001437749-25-030631-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/811641/000143774925030631/iccc20251007_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T04:31:36.049108+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}